Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial.
Nuplazid did not improve symptoms as an adjunctive treatment in adult patients with schizophrenia who had shown persistent inadequate response to their current antipsychotic therapy.
In a trial of 396 patients with moderate-to-severe psychotic symptoms, the drug did not show statistically significant improvements when given on top of patients existing antipsychotic treatments, compared to placebo.
